Magnetic Beads with High Ligand Density for Unclarified Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current magnetic adsorbent beads are not suitable for large-scale separation of biopharmaceuticals, particularly monoclonal antibodies, due to a lack of suitable beads and process designs, limiting their use in high-volume processing.
Innovation Solution
Development of magnetic beads with a porous matrix and embedded magnetic particles, coated with at least 10 mg/ml Fc-binding proteinaceous ligands, enabling high binding strength and capacity for immunoglobulins, allowing direct separation from unclarified cell cultures and efficient recovery processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional magnetic adsorbent beads are used, then small scale lab separations can be performed, but large scale separation of biopharmaceuticals cannot be achieved
Solution Approach 1:
The patent employs a porous polymer matrix as the support structure for magnetic beads, providing high surface area and porosity to accommodate large amounts of Fc-binding ligands. This porous structure enables the beads to achieve high binding capacity for immunoglobulins while maintaining mechanical stability for large-scale processing operations.
Solution Approach 2:
The invention creates a composite magnetic bead system combining magnetic particles embedded in a porous polymer matrix, with Fc-binding proteinaceous ligands covalently coupled to the matrix. This composite structure integrates the magnetic properties needed for separation with the high binding capacity required for large-scale biopharmaceutical processing.
2Productivity
If clarification of cell culture is performed before separation, then separation efficiency is improved, but processing time and complexity increase
Solution Approach 1:
The patent modifies the parameters of the magnetic beads by incorporating high concentrations of Fc-binding ligands (at least 10 mg/ml) covalently coupled to the porous matrix. This parameter change enables the beads to bind immunoglobulins effectively even in unclarified cell cultures, eliminating the need for separate clarification steps and simplifying the overall process.
3Reliability
If Fc-binding proteinaceous ligands are covalently coupled to porous polymer at high concentration, then binding strength and capacity for immunoglobulins is improved, but manufacturing complexity increases
Solution Approach 1:
The patent performs preliminary covalent coupling of Fc-binding proteinaceous ligands to the porous polymer matrix during bead manufacturing, ensuring high ligand concentration (at least 10 mg/ml) is achieved before the beads are used for separation. This preliminary action guarantees high binding strength and capacity while establishing a standardized manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The magnetic beads facilitate selective binding and high-yield recovery of immunoglobulins with favorable adsorption isotherms, enabling efficient separation and purification of biopharmaceuticals without prior clarification of cell cultures, enhancing large-scale processing capabilities.
Implementation Method 1
retaining the beads with a magnetic field
Implementation Method 2
at least 10 mg/ml Fc-binding proteinaceous ligands covalently coupled to the porous polymer
Data Source
AI summary
The invention discloses an immunoglobulin-binding magnetic bead, comprising a porous matrix and one or more magnetic particles embedded in said matrix, wherein said matrix comprises a porous polymer and at least 10 mg/ml Fc-binding proteinaceous ligands covalently coupled to said porous polymer.